¿Qué es la eritromelalgia?

1. Davis MD, O’Fallon WM, Rogers RS 3rd, Rooke TW. Natural history 562  of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000;136(3):330-336.

2. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41(3):171-174.

3. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper-or hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A. 2006;103(21):8245-8250.

4. McDonnell A, Schulman B, Ali Z, et al. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain. 2016;139(pt 4):1052-1065.

5. Waxman SG, Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med. 2005;11(12):555-

6. Burns TM, Te Morsche RH, Jansen JB, Drenth JP. Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia. Br J Dermatol. 2005;153(1):174-177.

7. Davis MD, Sandroni P, Rooke TW, Low PA. Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia. Arch Dermatol. 2003;139(10):1337-1343.

8. Ørstavik K, Mork C, Kvernebo K, Jorum E. Pain in primary erythromelalgiada neuropathic component? Pain. 2004;110(3):531-538.

9. Mantyh WG, Dyck PJ, Dyck PJ, et al. Epidermal nerve fiber quantification in patients with erythromelalgia. JAMA Dermatol. 2017;153(2):162-167.

10. Mork C, Kvernebo K. Erythromelalgia. In: Lebwohl M, Heymann WR, Coulson I, Murrell DF, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 6th ed. Elsevier; 2022.

11. Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia. Arch Dermatol. 2002;138(1):17-19.

12. Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005;141(10): 1320-1321.

13. Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? Arch Dermatol. 2006;142(3):283-286.

14. Poterucha TJ, Weiss WT, Warndahl RA, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol. 2013;12(3):308-310.

15. AlgoTx. FDA grants ATX01 orphan drug designation in erythromelalgia. 2020. Accessed July 8, 2022. https://algotx.com/fdagrants-atx01-orphan-drug-designation-in-erythromelalgia/16. Capsaicin. IBM Micromedex Solutions. Accessed May 19, 2022. http://www.micromedexsolutions.com

17. Muhiddin KA, Gallen IW, Harries S, Pearce VR. The use of capsaicin cream in a case of erythromelalgia. Postgrad Med J. 1994;70(829):841-843.

18. Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. 2000:841-847. 43(5)(pt 1).

19. Low SA, Robbins W, Tawfik VL. Complex management of a patient with refractory primary erythromelalgia lacking a SCN9A mutation. J Pain Res. 2017;10:973-977.

20. Davis MD, Morr CS, Warndahl RA, Sandroni P. Topically applied midodrine, 0.2%, an a1-agonist, for the treatment of erythromelalgia. JAMA Dermatol. 2015;151(9):1025-1026.

21. Hou JL, Onajin O, Gangat N, Davis MD, Wolanskyj AP. Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2017;58(3):715-717.

22. Kurzrock R, Cohen PR. Erythromelalgia: review of Clinical characteristics and pathophysiology. Am J Med. 1991;91(4): 416-422.

23. Calderone DC, Finzi E. Treatment of primary erythromelalgia with piroxicam. J Am Acad Dermatol. 1991;24(1):145-146.

24. Pagani-Estevez GL, Sandroni P, Davis MD, Watson JC. Erythromelalgia: identification of a corticosteroid-responsive subset. J Am Acad Dermatol. 2017;76(3):506-511.e1.

25. Cregg R, Cox JJ, Bennett DL, Wood JN, Werdehausen R. Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. Br J Pharmacol. 2014;171(19):4455-4463.

26. Iqbal J, Bhat MI, Charoo BA, Syed WA, Sheikh MA, Bhat IN. Experience with oral mexiletine in primary erythromelalgia in children. Ann Saudi Med. 2009;29(4):316-318.

27. Geha P, Yang Y, Estacion M, et al. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic análisis and functional profiling. JAMA Neurol. 2016;73(6):659-667.

28. Meijer IA, Vanasse M, Nizard S, Robitaille Y, Rossignol E. An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder. Muscle Nerve. 2014;49(1):134-138.

29. Nwebube C, Bulancea S, Marchidann A, Bello-Espinosa L, Treidler S. Erythromelalgia: a child with V400M mutation in the SCN9A gene. Neurol Genet. 2021;7(2):e570.

30. Yang Y, Adi T, Effraim PR, Chen L, Dib-Hajj SD, Waxman SG. Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Nav 1.7 mutation I234T. Br J Pharmacol. 2018;175(12):2261-2271.

31. Goldberg YP, Price N, Namdari R, et al. Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012;153(1):80-85.

32. Cao L, McDonnell A, Nitzsche A, et al. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci Transl Med. 2016;8(335):335ra56.

33. Kuhnert SM, Phillips WJ, Davis MD. Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol. 1999;135(12):1447-1449.

34. Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics. 2005;115(4):e504-e507.

35. Masic D, Liang E, Long C, Sterk EJ, Barbas B, Rech MA. Intravenous lidocaine for acute pain: a systematic review. Pharmacotherapy. 2018;38(12):1250-1259.<